REDWOOD CITY, Calif. – Biotricity has made its Bioflux mobile cardiac telemetry solution commercially available. The device’s technology is designed to support the diagnosis of cardiac arrhythmias, enhance patient outcomes and help reduce health care costs. “Bioflux was built for cardiac patients who require active monitoring because, until now, short-term monitoring or admission into the hospital for long-term observation was the standard,” said Waqaas Al-Siddiq, founder and CEO of Biotricity, in a statement. “Our technology addresses the multibillion-dollar cardiac-monitoring market in an innovative way.” The Bioflux system consists of the Bioflux device, software and a 24/7 monitoring center that merges with physicians’ existing platforms and workflows. The device monitors a patient’s electrocardiogram in near real-time, constantly analyzing and collecting data on the device and periodically uploading to the cloud via embedded cellular technology. Both symptomatic and asymptomatic patient symptoms are reviewed and triaged for each patient throughout the monitoring period.
You are here: / / Biotricity makes Bioflux commercially available